HIV vaccine - Immune response

Drugs in R and D

Volumn 3, Issue 6, 2002, Pages 411-420

  Qiao, Dan ^a   Zeeman, Anne Marie ^b   Deng, Wei ^a   Looijenga, Leendert H J ^b   Lin, Haifan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AG 1661; AMPRENAVIR; DIDANOSINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; INTERLEUKIN 2; IR 8101; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NUCLEOSIDE ANALOG; OLIGONUCLEOTIDE; PROTEINASE INHIBITOR; RG 83894; SAQUINAVIR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE; MYALGIA; NONHUMAN; PAIN; PRIORITY JOURNAL; VIRUS LOAD;

EID: 0038302243     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203060-00011     Document Type: Article

References (31)

1. Kahn JO, Cherng DW, Mayer K, Murray H, 806 Investigators Team, et al. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA : Journal of the American Medical Association 284: 2193-2202, 1 Nov 2000
2. Immune Response Corporation. The Immune Response Corporation announces publication of study suggesting that REMUNE (TM) induces HIV-1 specific T helper immune responses that correlate with control of virus. Media Release: [3 pages], 23 Apr 2001. Available from URL: http://www.imnr.com
3. Immune Response Corporation. The Immune Response Corporation presents Remune (Rm) data at the Second Annual Institute of Human Virology Meeting. Media Release: [2 pages], 22 Sep 1997
4. Craig C. FDA expands access to Immune Response's to HIV vaccine. Bioworld Today 7: 1-2, 15 Oct 1996
5. Immune Response Corporation. The Immune Response Corporation reports findings from phase II clinical trial of REMUNE in HIV-infected patients. Media Release: [3 pages], 1 Jun 2001. Available from URL: http://www.imnr.com
6. Immune Response Corporation. New virological findings from phase II clinical trial of REMUNE (TM) presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Media Release: [2 pages], 11 Jul 2001. Available from URL: http://www.imnr.com
7. The Immune Response Corporation announces Remune clinical data from phase II combination drug trial. PR Newswire [online]: [2 pages], 27 Oct 1998. Available from URL: http://www.newspage.com
8. Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, et al. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. Journal of Infectious Diseases 180: 626-640, Sep 1999
9. Jensen BK, Wilson J, Heald D. Effect of RG 83894 (Salk HIV immunogen) on the steady-state pharmacokinetics of zidovudine and didanosine in HIV-positive patients. Pharmaceutical Research 11 (Suppl): 430, Oct 1994
10. Immune Response. Immunization With REMUNE(R) in Immunocompetent HIV-Infected Patients May Lead To Stronger Immune Responses and Possible Control of Viral Replication Media Release: 13 May 2002. Available from URL: http://www.imnr.com
11. Moss RB, Diveley J, Jensen F, Carlo DJ. In vitro immune function after vaccination with an inactivated, gp120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine 18: 1081-1087, 6 Jan 2000
12. Immune Response Corporation. Animal study suggests intranasal delivery of HIV-1 antigen with adjuvant may induce potent immune responses capable of protection against viral challenge. Media Release: 26 Feb 2002. Available from URL: http://www.imnr.com
13. Immune Response Corporation. The Immune Response Corporation Releases Results for an AIDS Preventative Vaccine Candidate. Media Release: 30 May 2002. Available from URL: http://www.imnr.com
14. Valentine FT, De Gruttola V, Kaplan M, See D, Flynn N, et al. Effects of HAART compared to HAART plus an inactivated HIV immunogen on lymphocyte proliferative responses to HIV antigens. 12th World AIDS Conference Supplement: 26, 28 Jun 1998
15. Patterson BK, Carlo DJ, Kaplan MH, Marecki M, Pawha S, et al. Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen. AIDS 13: 1607-1611, 10 Sep 1999
16. Kahn J, Lagakos S, Mayer K, Murray H. A randomized, placebo controlled multicenter study of Remune in subjects with 300-550 CD4 cells and unrestricted anti-retroviral treatments. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: late breaker abstracts: 18, 26 Sep 1999
17. Immune Response Corporation. Interim results in a patient subset indicate that treatment with REMUNE (TM) and antiviral drugs may stimulate killer T cell activity. Media Release: [3 pages], 21 Jun 2000. Available from URL: http:// www.imnr.com
18. Immune Response Corporation. Additional data on REMUNE (R) from Spanish phase II trial STIR 2102 presented at Ninth Conference on Retroviruses and Opportunistic Infections immunologic results demonstrate statistically significant restoration of key immune function in HIV-infected patients. Media Release: 28 Feb 2002. Available from URL: http://www.imnr.com
19. Immune Response Corporation. Clinical data on REMUNE (TM) (investigational HIV-1 immunogen) selected as a late breaker presentation at the XIII International AIDS Conference in Durban, South Africa. Media Release: [3 pages], 14 Jul 2000. Available from URL: http://www.imnr.com
20. The Immune response Corporation announces publication of results from Thailand clinical trial. PR Newswire [online]: [2 pages], 26 Aug 1998. Available from URL: http://www.newspage.com
21. The Immune Response Corporation announces favorable results from the Thailand clinical trial. PR Newswire [online]: [2 pages], 13 Feb 1998. Available from URL: http://www.newspage.com
22. The Immune Response Corporation. The Immune Response Corporation Announces Results From Trial of REMUNE(R) In Treatment Interruptions for Chronic HIV Infection. Media Release: 15 Aug 2002. Available from URL: http://www.imnr.com
23. Immune Response Corporation. HIV therapy with Remune(TM) appears to reconstitute helper T-cell responses against the virus in patients on antiviral drug therapy. Research supports synergism between remune and antiviral drugs. Media Release: [1 page], 13 Apr 2000. Available from URL: http://www.imnr.com/
24. Immune Response Corporation. The Immune Response Corporation announces REMUNE(TM) appears to stimulate broad cross reactive immune responses to several different strains of HIV and the patients own virus. Media Release: [2 pages], 6 Mar 2000. Available from URL: http://www.imnr.com
25. Moss RB, Wallace MR, Giermakowska WK, Webb E, Savary J, et al. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen. Journal of Infectious Diseases 180: 641-648, Sep 1999
26. Immune Response Corporation. The Immune Response Corporation publishes data in Proceedings of the National Academy of Sciences suggesting a correlation between HIV-specific immune responses and favorable clinical status. Media Release: [3 pages], 15 Oct 1999. Available from URL: http://www.imnr.com
27. Immune Response Corporation. The Immune Response Corporation announces results from a phase II clinical trial of REMUNE in Thailand at the WHO-UNAIDS Vaccine Advisory Committee Meeting. Media Release: [2 pages], 23 Feb 2000. Available from URL: http://www.imnr.com
28. Churdboonchart V, Sakondhavat C, Kulpradist S, Isarangkura Na Ayudthya B, Chandeying V. et al. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of greater than 300. Clinical and Diagnostic Laboratory Immunology 7: 728-733, Sep 2000
29. Trinity Medical Group USA. Trinity Medical Group USA announces publication of REMUNE (R) study results at 132 weeks. Media Release: [3 pages], 26 Oct 2001. Available from URL: http://www.trinitymg.com
30. Trinity Medical Group USA Inc. Trinity Medical Group USA Announces REMUNE(R) Study Results In Slowing HIV Progression and Overcoming Specific Drug Resistance In Anti-retroviral Therapies. Media Release: 22 Aug 2002. Available from URL: http://www.trinitymg.com
31. Immune Response Corporation. The Immune Response Corporation Announces Presentation of Study Results On REMUNE(R)'s Potential for Treating Chronically Infected HIV-Positive Patients. Media Release: 8 Jul 2002. Available from URL: http://www.imnr.com